BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27328730)

  • 1. Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia.
    Chen JL; Walton KL; Qian H; Colgan TD; Hagg A; Watt MJ; Harrison CA; Gregorevic P
    Cancer Res; 2016 Sep; 76(18):5372-82. PubMed ID: 27328730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of activins promotes muscle wasting and cachexia.
    Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
    FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
    Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia.
    Pettersen K; Andersen S; van der Veen A; Nonstad U; Hatakeyama S; Lambert C; Lach-Trifilieff E; Moestue S; Kim J; Grønberg BH; Schilb A; Jacobi C; Bjørkøy G
    J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):195-207. PubMed ID: 31436048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
    Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
    Togashi Y; Kogita A; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Kitano M; Okuno K; Kudo M; Nishio K
    Cancer Lett; 2015 Jan; 356(2 Pt B):819-27. PubMed ID: 25449777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice.
    Walton KL; Chen JL; Arnold Q; Kelly E; La M; Lu L; Lovrecz G; Hagg A; Colgan TD; Qian H; Gregorevic P; Harrison CA
    Endocrinology; 2019 Oct; 160(10):2417-2426. PubMed ID: 31322699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
    Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
    Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
    Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
    Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
    Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
    Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin-β(c) reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice.
    Gold E; Marino FE; Harrison C; Makanji Y; Risbridger G
    J Pathol; 2013 Mar; 229(4):599-607. PubMed ID: 23180294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle NAD
    Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
    Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
    Coerver KA; Woodruff TK; Finegold MJ; Mather J; Bradley A; Matzuk MM
    Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
    Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
    Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
    Cipriano SC; Chen L; Kumar TR; Matzuk MM
    Endocrinology; 2000 Jul; 141(7):2319-27. PubMed ID: 10875231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
    Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
    Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft.
    Tamura S; Ouchi KF; Mori K; Endo M; Matsumoto T; Eda H; Tanaka Y; Ishitsuka H; Tokita H; Yamaguchi K
    Clin Cancer Res; 1995 Nov; 1(11):1353-8. PubMed ID: 9815931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
    Matsuyama T; Ishikawa T; Okayama T; Oka K; Adachi S; Mizushima K; Kimura R; Okajima M; Sakai H; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Kokura S; Naito Y; Itoh Y
    Int J Cancer; 2015 Dec; 137(11):2558-65. PubMed ID: 26016447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
    Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
    Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. InACTIVatINg cancer cachexia.
    Mathew SJ
    Dis Model Mech; 2011 May; 4(3):283-5. PubMed ID: 21372048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.